News & Events


Recent Firm Activities and Highlights

Boston Millennia Parters
BC Platforms to Partner with Microsoft
11.28.16
BC Platforms, a world leader in genomic data management solutions, today announced that it will collaborate with Microsoft to provide integrated genomic data management solutions in the cloud to Codigo46. Codigo46, an emerging Mexican company, is building and managing the largest biobank in Latin-America in co-operation with Mexican health and research authorities. Codigo46 will genotype one million Mexican subjects in the next three years for the purpose of delivering personalized medicine benefits to patients. BC Platforms signed a partnership with Codigo46 in July 2016. Read Full Release
Boston Millennia Parters
BMP Invests in BC Platforms
11.24.16
The investment is a significant milestone in BC Platforms’ success and growth in North America as we roll-out our US expansion with headquarters in Boston. The Boston area boasts nearly 30,000 scientists and other workers directly involved in biotech, pharmaceutical and clinical research, the highest concentration of life-science research workers in the U.S. We are glad to have BMP as a partner to facilitate our ambitious development goals in the No. 1 U.S. life science hub. Read Full Release
Boston Millennia Parters
Dana Callow to Speak on The State of The VC Market Panel
11.17.16
ACG Boston's regular networking breakfast returns to Serafina in Boston's financial district. Open to all, the Networking Breakfast is ACG Boston's signature event, where M&A professionals come to network and hear industry experts share their outlook, opinions, successes and failures. Join New England's M&A community on November 17 to hear a panel discussion on the current state of the VC market -- how the industry has evolved and where it's headed in the future. Read Full Release
Boston Millennia Parters
Will value-based payment initiatives continue under Trump?
11.11.16
President-elect Donald Trump's promise to dismantle the Affordable Care Act is unlikely to also undo widespread efforts to nudge the U.S. healthcare system toward value-based payment, including experiments devised by the ACA-funded CMS Innovation Center. Read Full Release
Boston Millennia Parters
3Derm October Newsletter
10.31.16
It's that time of year in Boston when you have 75 degree weekends followed immediately by 35 degree Mondays. We get it, Beantown is not an ideal destination at the moment. HOWEVER, this week our team will be opening up our office to advisors, investors, and other industry minds to hold a week of BrainTrust™ brainstorming sessions that cover Product Strategy, Workflow and Operations, Future Technology, and Marketing and Productizing. Video conference attendees are welcome. Read Full Release
MedAptus
MedAptus Hospitalist Customers Leverage Real-Time Data to Manage Patient Risk
10.20.16
MedAptus® today announced the availability of real-time analytics, the Hospitalist Risk Series, that leverage patient history and admission activity to identify those at greatest risk for re-admissions, and also helps providers better manage resources related to length of stay. The new Series, aimed primarily at hospitalists on the front line of acute patient care, is available through the MedAptus Professional Charge Capture (Pro) suite. This latest offering extends the Pro solution’s ability to compute data from admission/discharge feeds and diagnosis history in order to meaningfully impact key metrics around hospitalizations that hospital medicine providers are increasingly responsible for. Read Full Release
Boston Millennia Parters
Report of the Cancer Moonshot Task Force
10.17.16
While bold, the goal of the Cancer Moonshot is within our grasp. Today, society has the benefit of decades of scientific understanding and vast amounts of rich data just waiting to be transformed into solutions. We now know that cancer is hundreds of diseases, largely of our genome, and we have developed new and innovative ways of capitalizing on this knowledge. We know that our behavior and environment contribute to our likelihood of getting cancer, and we are modifying our behaviors and exposures to avoid known risks. We know that prevention and early diagnosis are key to fighting cancer, and we can build these efforts into clinical care. Read Full Release
Odyssey Logistics & Technology
Proposed Truck Speed Limiters Expected to Improve Highway Safety
10.17.16
The U.S. Department of Transportation (DOT) is proposing a new rule that would set maximum travel speeds for heavy-duty vehicles. Set forth by the DOT’s National Highway Traffic Safety Administration (NHTSA) and Federal Motor Carrier Safety Administration (FMCSA), the new rule is expected to save lives and more than $1 billion in fuel annually. Read Full Release
Boston Millennia Parters
BMP to attend 2016 SBIR New England Regional Summit
10.06.16
The 2016 New England Regional Innovation Summit is a two-day engagement opportunity being held at MIT, for technology innovators and entrepreneurs. This effort, spearheaded by the SBA Office of Investment and Innovation (OII), is a coordinated effort amongst participating SBIR/STTR agencies to continually engage, identify, and encourage participation in the SBIR/STTR programs. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, affectionately referred as America’s Seed Fund, play an instrumental role in providing early stage, non-dilutive, research and development capital which spurs small advanced technology firms’ innovations. Annually more than $2.5 billion non-diluted in early stage research and development funding is provided through these programs. Read Full Release
Collegium Pharmaceutical
Despite Recent Performance We Still See Room for Upside Given United Win and Xtampza ER Tailwinds for 2017
10.03.16
Following recent share performance that has shares almost doubling in the past two weeks, we continue to see room for share appreciation as the Xtampza ER launch has clear tailwinds as we exit the summer through 2017. Management has signed at least one large managed care win with UnitedHealth (UNH $140.00) and we believe additional managed care wins are likely during the fourth quarter as well as the potential for comparative data between OxyContin and Xtampza ER being added to label. Admittedly, the Xtampza ER launch was slow as management chose to launch during the summer months despite the historically slow season, which was compounded by a lack of approved marketing materials. However, the company recently received approved marketing materials and given formulary wins (both UnitedHealth and likely additional wins), we should see a ramping up of scripts over the next quarter and into 2017. Read Full Release